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Human immunodeficiency virus (HIV) damages the body’s 
immune system, making secondary (or opportunistic) 
infections more common. Treatment and prevention of such 
infections is integral to the management of patients with HIV 
infection. Co-trimoxazole is a prophylactic treatment that has a 
wide range of action against common bacteria, parasites, fungi 
and yeasts. As part of a minimum care package, UNAIDS/
WHO recommends co-trimoxazole prophylaxis for HIV-
infected adults with symptomatic disease (WHO stage II, III 
or IV), or asymptomatic individuals with CD4 counts ≤500 
cells/µl, and for all HIV-positive pregnant women after the 
first trimester.1 Co-trimoxazole is also recommended for use in 
children with proven HIV infection and infants exposed to HIV 
(from 4 - 6 weeks of age until infection with HIV is ruled out).2
The object of this report is to summarise the effects of         
co-trimoxazole prophylaxis on morbidity and mortality among 
HIV-infected individuals.
Beneficial effects
In HIV-positive adults not receiving antiretroviral therapy 
(ARV), a Cochrane Review (including three randomised 
controlled trials (RCTs)) found that co-trimoxazole prophylaxis 
reduced the risk of death by almost a third (Table I).3 The 
beneficial effect was similar for early (CD4 ≥200 cells/µl) 
and advanced (CD4 <200 cells/µl) disease. The frequency of 
admissions to hospital and the incidence of bacterial, parasitic 
and Pneumocystis carinii pneumonia (PCP) infections were also 
significantly reduced (Table I). A further RCT among HIV-
positive adults in Malawi newly diagnosed with tuberculosis4 
found no significant difference in bacterial pneumonia (hazard 
ratio (HR) 1.07 (95% confidence interval (CI) 0.56 - 2.06)) 
and the probability of survival (HR 1.11 (95% CI 0.72 - 1.71)) 
between participants allocated 480 mg v. 960 mg of  
co-trimoxazole.
In children, support for co-trimoxazole prophylaxis came 
from a randomised placebo-controlled trial (N=541) conducted 
in an area in Zambia with high levels (60 - 80%) of in vitro 
resistance to this antibiotic.5,6 Children ≤5 years were given 
a daily dose of 240 mg co-trimoxazole while those >5 years 
received a daily dose of 480 mg. Co-trimoxazole significantly 
reduced mortality by 33% (RR 0.67; 95% CI 0.53 - 0.85) and 
hospital admission rates by 23% (RR 0.77; 95% CI 0.62 - 0.95). 
Follow-up was reported to be excellent and few patients 
stopped their medication. The beneficial effect was seen 
across all ages and CD4 counts, and effectiveness of the drug 
did not diminish during periods of use up to 18 months’ 
administration.
Harmful effects
The Cochrane Review found a higher risk of adverse effects 
in adults on co-trimoxazole compared with placebo, but this 
difference was not statistically significant (Table I). The RCT 
in Zambian children found no difference between treatment 
and control groups in the incidence of one or more grade 3 or 4 
adverse drug reactions (HR 0.76; 95% CI 0.39 - 1.5). No allergic 
reactions to co-trimoxazole occurred in this study. In HIV-
infected patients with a previous history of mild or moderate 
hypersensitivity to co-trimoxazole who required prophylaxis, 
desensitisation (stopping treatment and recommencing 
treatment with dose escalation over a period of days) 
compared with co-trimoxazole rechallenge (stopping treatment 
and starting at the full dose) resulted in fewer treatment 
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Table I. Effects of co-trimoxazole v. placebo (Cochrane 
Review)3
   No. of    No. of               
Outcome   trials   participants      RR (95% CI)
Death        3     1 318            0.69 (0.55 - 0.87)
Hospital admissions      3        764            0.66 (0.48 - 0.92)
Serious morbid events   3     1 384            0.76 (0.64 - 0.90)
Bacterial infections       3     1 405            0.48 (0.37 - 0.62)
Parasitic infections       3     1 405            0.37 (0.24 - 0.58)
Pneumocystis carinii        1          60            0.31 (0.13 - 0.74) 
pneumonia (PCP)    
Adverse events       3     1 405            1.28 (0.47 - 3.51)
RR = relative risk
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discontinuations before 6 months (RR 0.64; 95% CI 0.45 - 0.91) 
and overall adverse reactions (RR 0.51; 95% CI 0.36 - 0.73).7
Comments
No randomised studies provide information on the optimal 
time for initiating prophylaxis in adults, or on when to 
stop prophylaxis. None of the trials included in the review 
focused on patients receiving treatment with antiretrovirals. 
Current studies neither report on the effects of prolonged                     
co-trimoxazole use on bacterial resistance nor evaluate whether 
co-trimoxazole affects resistance of malaria parasites to 
sulfadoxine pyrimethamine (with which co-trimoxazole shares 
a component).
Conclusions
Co-trimoxazole is highly effective in reducing mortality and 
morbidity in HIV-infected adults and children not receiving 
antiretroviral treatment. Similar benefits are seen in early 
and advanced HIV disease. Co-trimoxazole is well tolerated, 
with minimal side-effects. Further research is required on the 
optimal time for commencement of co-trimoxazole prophylaxis 
and to evaluate its use in patients on antiretrovirals.
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Our approach to cervical cancer prevention is set to change 
dramatically over the next decade with the advent of human 
papillomavirus (HPV) DNA typing, the probable demise of the 
PAP smear as we know it, and the registration of two highly 
effective vaccines against the two main HPV types (16 and 18). 
The latter account for about 70% of all cervical cancer cases 
globally and for 63% of those in South African women.1 HPV-45 
and HPV-31 account for another 10% of cases.2,3 
Except for a minority of non-mainstream, but remarkably 
visible and vocal, groups and individuals the general consensus 
worldwide is that HPV vaccines herald a new era and a 
phenomenal advance in the fight against cervical cancer, the 
most common cancer to affect women in South Africa and sub-
Saharan Africa, where the established co-factors of smoking, 
long-term oral contraceptive use, HIV co-infection and high 
parity are also operative.4 Lesotho has the unfortunate claim 
of the highest rate of cervical cancer in the world, with an age-
standardised incidence rate of 61.6 (versus our 37.5) per 100 000 
women.5 
Women and health care providers have had to make two 
paradigm shifts around cervical cancer: firstly, although 
most HPV infections clear naturally, persistent infection with 
particular genotypes of a virus are responsible for most cases of 
cervical cancer (including the less common adenocarcinoma),6   
and secondly, close contact (as in both penetrative and non-
penetrative sex) is the main mode of infection. 
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